Can we create new biological therapies with machine-guided design? Today I chat with Peyton Greenside, Co-Founder and CSO of BigHat Biosciences, on using machine learning to design therapeutic proteins, the advantages of using "smart" data over "big" data, and the importance of interpretability.

Check out the glossary of terms, definitions, and resources (and get a sneak peak of the future conversations lined up!) here: bit.ly/datapulse-glossary

Podden och tillhörande omslagsbild på den här sidan tillhör Anika Gupta. Innehållet i podden är skapat av Anika Gupta och inte av, eller tillsammans med, Poddtoppen.

Senast besökta

The Data Pulse

Biologics and active learning in ML with Peyton Greenside (BigHat Biosciences)

00:00